dc.contributor.author | Barrios del Pino, Yvelise | |
dc.contributor.author | Franco, Andrés | |
dc.contributor.author | Alava-Cruz, Cristina | |
dc.contributor.author | Cuesta-Martín, Ricardo | |
dc.contributor.author | Camara, Carmen | |
dc.contributor.author | Matheu, Victor | |
dc.contributor.other | Medicina Interna, Dermatología y Psiquiatría | |
dc.contributor.other | Hospital Universitario de Canarias | |
dc.date.accessioned | 2023-12-19T21:08:22Z | |
dc.date.available | 2023-12-19T21:08:22Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://riull.ull.es/xmlui/handle/915/34912 | |
dc.description.abstract | Background: Patients with primary antibody deficiencies, such as Common Variable
Immunodeficiency (CVID), have some problems to assess immune response after coronavirus
disease (COVID) vaccination. Cutaneous delayed-type hypersensitivity (DTH) has the potential
to be used as a useful, simple, and cheaper tool to assess T-cell (T lymphocyte) function.
Methods: Seventeen patients with CVID, a rare disease, received two doses of the mRNA-based
Pfizer-BioNTech COVID-19 vaccine. Humoral Immune Response (HIR) was determined by measuring specific immunoglobulin G (IgG) antibodies, and Cellular Immune Response (CIR) was
evaluated using an ex vivo interferon-gamma release assay (IGRA) and in vivo by DTH skin test.
Results: Two weeks after the second dose of the vaccine, 12 out of 17 CVID patients have high
optical density (OD) ratios of specific anti-spike protein (S) IgG whereas five patients were
negative or low. Ex vivo CIR was considered positive in 14 out of 17 S1-stimulated patients.
Unspecific stimulation was positive in all 17 patients showing no T-cell defect. A positive DTH
skin test was observed in 16 CVID patients. The only patient with negative DTH also had negative ex vivo CIR.
Conclusions: The use of DTH to evaluate CIR was validated with an optimal correlation with
the ex vivo CIR. The CIR after vaccination in patients with antibody deficiencies seems to have
high precision and more sensitivity to antibodies-based methods in CVID.
Clinical Implications: There is a remarkable correlation between cutaneous DTH and ex vivo
IGRA after COVID vaccination. A COVID-specific skin DTH test could be implemented in large
populations. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | en | |
dc.relation.ispartofseries | Allergologia et immunopathologia, 2022;50(3):101–105 | |
dc.rights | Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional) | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES | |
dc.title | Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients. | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.15586/aei.v50i3.583 | |
dc.subject.keyword | Common Variable Immunodeficiency (CVID) | en |
dc.subject.keyword | Immunodeficiency | en |
dc.subject.keyword | rare disease | en |
dc.subject.keyword | T-cell response | en |
dc.subject.keyword | COVID vaccination | en |
dc.subject.keyword | DTH | en |
dc.subject.keyword | skin test | en |
dc.subject.keyword | SARS-CoV-2 | en |
dc.subject.keyword | antibody deficiency | en |